Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
ROVI reports operating revenue growth of 12% and net profit growth of 53%
ROVI reports operating revenue growth of 12% and net profit growth of 53%
Today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaging in the...
5 min
24/11/2020
First nine months 2020 Results Press Release
0 min
05/11/2020
First nine months 2020 results presentation
0 min
05/11/2020